Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Citi
Fuji
Farmers Insurance
Daiichi Sankyo
US Department of Justice
Julphar
Merck
Cantor Fitzgerald

Generated: May 25, 2018

DrugPatentWatch Database Preview

MYCOBUTIN Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Mycobutin, and when can generic versions of Mycobutin launch?

Mycobutin is a drug marketed by Pharmacia And Upjohn and is included in one NDA.

The generic ingredient in MYCOBUTIN is rifabutin. There are three drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the rifabutin profile page.
Drug patent expirations by year for MYCOBUTIN
Pharmacology for MYCOBUTIN
Ingredient-typeRifamycins
Drug ClassRifamycin Antimycobacterial
Medical Subject Heading (MeSH) Categories for MYCOBUTIN
Synonyms for MYCOBUTIN
(7S,11S,12R,13S,14R,15R,16R,17S,18S)-2,15,17-trihydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23,32-trioxo-8,33-dioxa-24,27,29-triazaspiro[pentacyclo[23.6.1.1;{4,7}.0;{5,31}.0;{26,30}]tritriacontane-
(9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6-16,18,20- TETRAHYDROXY-1'-ISOBUTYL-14-METHOXY-7,9,15,17,19,21,25- HEPTAMETHYLSPIRO(9,4-(EPOXYPENTADECA(1,11,13)TRIENIMINO)-2H- FURO(2',3':7,8)NAPHTH(1,2-D)IMIDAZOLE-2,4'-PIPE
(9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6-16,18,20-Tetrahydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethylspiro(9,4-(epoxypentadeca(1,11,13)trienimino)-2H-furo(2',3':7,8)naphth(1,2-d)imidazole-2,4'-piperid
(9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6,18,20-trihydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethyl-5,10,26-trioxo-3,5,9,10-tetrahydrospiro[9,4-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[
(trihydroxy-1'-isobutyl-methoxy-heptamethyl-trioxo-spiro[[?]-4,4'-piperidine]yl) acetate
1,4-dihydro-1-deoxy-1?,4-didehydro-5?-(2-methylpropyl)-1-oxo-rifamycinxi;1,4-dihydro-1-deoxy-1?,4-didehydro-5?-(2-methylpropyl)-1-oxorifamycinxiv;
1,4-Dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxorifamycin XIV
1W306TDA6S
4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S
4-N-isobutylspiropiperidylrifamycin S
559R069
72559-06-9
AB01209745-01
AB01274733_02
AB01274733-01
AB2000265
AC-19109
AKOS015963033
Alfacid
Ambap72559-06-9
AN-37420
Ansamicin
Ansamycin
Ansatipin
Ansatipine
Antibiotic LM 427
Assatipin
ATEBXHFBFRCZMA-VXTBVIBXSA-N
BC214998
BRN 3584778
C07235
C46H62N4O11
CAS-72559-06-9
CCG-221109
CHEBI:45367
CHEMBL444633
D00424
D05CHI
DB00615
DRG-0085
DSSTox_CID_10773
DSSTox_GSID_33960
DSSTox_RID_79103
DTXSID0033960
Grunenthal Brand of Rifabutin
HMS1571M20
HMS3259D12
HSDB 3577
Kenfarma Brand of Rifabutin
LM 427
LM-427
LM427
LS-143839
MFCD00866816
MLS001061256
MolPort-005-938-065
Mycobutin (TN)
Mycobutin, Ansamycin, LM 427, Ansatipine, Rifabutin
Mycobutin;Ansamycin;LM 427;Ansatipine
NC00720
NCGC00090762-01
NCGC00090762-02
NCGC00258312-01
Pfizer Brand of Rifabutin
Prestwick2_001109
RBT
RIFABUTIN
Rifabutin (JAN/USP/INN)
Rifabutin [USAN:BAN:INN]
Rifabutin Pfizer Brand
Rifabutina
Rifabutina [Spanish]
Rifabutine
Rifabutine [French]
Rifabutinum
Rifabutinum [Latin]
Rifamycin XIV, 1,4-dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxo-
Rifamycin XIV, 1',4-didehydro-1-deoxy-1,4-dihydro-5'-(2-methylpropyl)-1-oxo-
SC-18287
SCHEMBL36043
SMR001227203
Spiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26(3H,9H)-trione, 16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-heptameth
Spiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26(3H,9H)-trione, 16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-heptamethyl-1'-(2-methylpropyl)-,
Tox21_111012
Tox21_200758
UNII-1W306TDA6S
ZINC169621215

US Patents and Regulatory Information for MYCOBUTIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn MYCOBUTIN rifabutin CAPSULE;ORAL 050689-001 Dec 23, 1992 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Deloitte
Daiichi Sankyo
Farmers Insurance
Covington
Teva
Johnson and Johnson
Citi
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.